TARGETING DRUG TO HIV SANCTUARY IN LYMPHATIC

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目及 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 淋巴结被认为为接受高效抗逆转录病毒治疗的患者提供了持续存在的储存库。 当药物治疗停止时，持续存在的病毒可以繁殖，导致病毒迅速返回到全身循环，并且经常出现耐药突变体。 我们的目标是使用靶向药物递送来增加抗HIV药物在淋巴结和淋巴组织中的浓度，从而减少或消除这些病毒库。 药物将通过掺入脂质体或脂质纳米颗粒而被靶向，已知脂质体或脂质纳米颗粒会在淋巴结中排出和积聚。 使用氟脱氧葡萄糖（F18-FDG）和正电子发射断层扫描（PET）是基于由于活跃的HIV复制导致的葡萄糖代谢增加来识别淋巴组织中的代谢活性。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The lymph nodes are thought to provided reservoirs where persists in patients undergoing highly active antiretroviral therapy. When drug therapy is discontinued, the persistent virus can multiply, leading to a rapid return of virus to the general circulation and frequently, the emergence of drug resistant mutants. Our objective is to use targeted drug delivery to increase the concentration of anti-HIV drugs in the lymph nodes and lymphoid tissues thus diminishing or elimination these viral reservoirs. Drugs will be targeted by incorporate into liposome or lipid nano-particles, which are known to drain and accumulate in the lymph nodes. Using fluorine deoxyglucose (F18-FDG) and positron emission tomography (PET) is to identify metabolic activity in lymphoid tissues based on increase glucose metabolism due to active HIV replication.